Received: 31 July 2019 | Revised: 3 January 2020 | Accepted: 23 February 2020

DOI: 10.1002/mus.26845

ISSUES & OPINIONS

MUSCLE&NERVE WILEY

Conference report on contractures in musculoskeletal and neurological conditions

Glen H. Nuckolls PhD[1] | Kathi Kinnett MSN, APRN[2] | Sudarshan Dayanidhi PT, PhD[3] | Andrea A. Domenighetti PhD[3] | Tina Duong MPT[4] | Yetrib Hathout PhD[5] | Michael W. Lawlor MD, PhD[6,7] | Sabrina S. M. Lee PhD[8] | S. Peter Magnusson PT, DMSc[9,10,11] | Craig M. McDonald MD[12,13] | Elizabeth M. McNally MD, PhD[14] | Natalie F. Miller DPT[15] | Bradley B. Olwin PhD[16] | Preeti Raghavan MD[17] | Thomas J. Roberts PhD[18] | Seward B. Rutkove MD[19] | John F. Sarwark MD[20] | Claudia R. Senesac PT, PhD[21] | Leslie F. Vogel MS PT[22] | Glenn A. Walter PhD[23] | Rebecca J. Willcocks PhD[21] | William Z. Rymer MD, PhD[3] | Richard L. Lieber PhD[3]

[1]Division of Neuroscience, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

[2]Parent Project Muscular Dystrophy, Hackensack, New Jersey

[3]The Shirley Ryan AbilityLab, Chicago, Illinois

[4]Department of Neurology, Stanford University, Palo Alto, California

[5]School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Johnson City, New York

[6]Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

[7]Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin

[8]Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois

[9]Department of Physical and Occupational Therapy, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

[10]Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen, Denmark

[11]Department of Orthopedic Surgery, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

[12]Department of Physical Medicine & Rehabilitation, University of California Davis School of Medicine, Sacramento, California

[13]Department of Pediatrics, University of California Davis School of Medicine, Sacramento, California

[14]Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois

[15]Center for Gene Therapy, Nationwide Children's Hospital, Columbus, Ohio

[16]Department of Molecular, Cellular, and Developmental Biology, University of Colorado at Boulder, Colorado

[17]Rusk Rehabilitation, New York University School of Medicine, New York, New York

[18]Ecology and Evolutionary Biology, Brown University, Providence, Rhode Island

[19]Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

[20]Department of Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois

[21]Physical Therapy Department, College of Public Health and Health Professions, University of Florida, Gainesville, Florida

[22]Department of Rehabilitation, Seattle Children's Hospital, Seattle, Washington

[23]Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida

Abbreviations: CP, cerebral palsy; DMD, Duchenne muscular dystrophy; ECM, extracellular matrix; EIM, electrical impedance myography; LMN, lower motor neuron; ROM, range of motion; UMN, upper motor neuron.

Correspondence
Glen H. Nuckolls, PhD, National Institute of Neurological Disorders and Stroke, 6001 Executive Blvd, Bethesda, MD 20892.
Email: glen.nuckolls@nih.gov

Funding information
This workshop was supported by National Institute of Child Health and Human Development, National Institute of Neurological Disorders and Stroke, Parent Project Muscular Dystrophy, and Shirley Ryan AbilityLab

Abstract

Limb contractures are debilitating complications associated with various muscle and nervous system disorders. This report summarizes presentations at a conference at the Shirley Ryan AbilityLab in Chicago, Illinois, on April 19–20, 2018, involving researchers and physicians from diverse disciplines who convened to discuss current clinical and preclinical understanding of contractures in Duchenne muscular dystrophy, stroke, cerebral palsy, and other conditions. Presenters described changes in muscle architecture, activation, extracellular matrix, satellite cells, and muscle fiber sarcomeric structure that accompany or predispose muscles to contracture. Participants identified ongoing and future research directions that may lead to understanding of the intersecting factors that trigger contractures. These include additional studies of changes in muscle, tendon, joint, and neuronal tissues during contracture development with imaging, molecular, and physiologic approaches. Participants identified the requirement for improved biomarkers and outcome measures to identify patients likely to develop contractures and to accurately measure efficacy of treatments currently available and under development.

KEYWORDS
cerebral palsy, contracture, Duchenne muscular dystrophy, muscle, stroke

1 | PURPOSE OF THE WORKSHOP

A research conference was held at the Shirley Ryan AbilityLab in Chicago, Illinois on April 19–20, 2018, to discuss the causes and treatments of contractures, debilitating consequences of a wide range of conditions including primary myopathies such as Duchenne muscular dystrophy (DMD), and neurological conditions that affect muscle such as stroke and cerebral palsy (CP). Presenters from the meeting are authors of this article. The goals of the meeting were to promote discussion and collaboration among researchers with diverse expertise, gain insights into the causes of contractures, assess biomarkers and current treatments, and identify gaps in understanding that, if addressed, could lead to more effective evidence-based treatments.

2 | CONTRACTURES AND PATIENT IMPACT

There is no universally accepted definition of limb contracture, but reduced range of motion (ROM) accompanied by increased mechanical resistance at the ends of the available range are accepted clinical signs. Contractures in neuromuscular conditions are associated with reduced muscle belly length, while tendon length is less affected.[1-3] Among the neurological and musculoskeletal conditions associated with contracture, the effects on muscle vary. Some conditions cause muscle hyperactivity, while others cause paralysis or degeneration of muscle fibers and replacement by noncontractile tissue. Muscle weakness or hyperactivity can increase joint static positioning, which may trigger contractures if other predisposing factors are present. Joint pain can be a predictor and/or consequence of contractures in some patients.[4,5] Contractures cause significant burden on patients due to altered body positioning, decreased independence in performing activities of daily living, and reduced community participation contributing to social isolation and decreased quality of life.

3 | CONTRACTURES IN DMD

Muscular dystrophies are associated with muscle weakness and the replacement of muscle by fat and fibrotic tissue, which contributes to contractures in some patients.[2] Researchers studying the natural history of DMD discussed data on the patterns of contracture involvement and progression. Altered gait biomechanics resulting from weakness in knee and hip extensors increases the risk that individuals will develop ankle equinus contracture prior to loss of ambulation, but wheelchair reliance is most frequently the result of muscle weakness rather than contractures.[6] Contractures develop in the hips and knees in individuals who are nonambulatory when static positioning is more prevalent and weakness does not allow full movement against gravity.[6-8] Subsequent upper extremity weakness leads to static positioning and contractures in the elbows and wrists. The inability of muscles to move a joint through the full ROM predisposes the joint to contracture.[2] Imbalance in the strength of opposing agonist and antagonist muscles may contribute to this inability in some conditions, although in DMD there is no association between muscle strength imbalance around a joint and contracture frequency or severity.[6] Contracture progression in DMD is further complicated by muscle fiber degeneration and tissue fibrosis.[2] Mouse models of

muscular dystrophies exhibit progressive muscle weakness and some exhibit muscle fibrosis, but dystrophic mice do not develop obvious contractures. Presenters described considerable variability in contracture formation in people living with DMD. For example, 50% of participants in an ongoing study of MRI biomarkers developed knee contractures >20° soon after loss of ambulation; however, 20% of participants maintained full ROM. (R. Willcocks, unpublished data, collected 2010-2018, communicated June 2019). Additional studies are required to identify genetic and/or environmental factors that allow some patients to avoid contractures.

4 | CONTRACTURES IN NEUROLOGICAL CONDITIONS

Contractures are associated with upper motor neuron (UMN) disorders (eg, CP, stroke) and lower motor neuron (LMN) disorders (eg, Charcot Marie Tooth disease). Weakness is common in UMN and LMN disorders. The limb muscles of patients with UMN disorders often exhibit spasticity, the velocity-dependent increase in tonic stretch reflexes that can lead to muscle overactivation or coactivation of antagonistic muscles resulting in muscle stiffness. However, spasticity is neither sufficient nor required for contractures to develop.[9]

Cellular and extracellular matrix (ECM) changes in muscle associated with contractures were discussed. Studies of tissue obtained from patients with CP provide evidence that the population of muscle-regenerating satellite cells is decreased by 60% to 70% in contracted muscle.[10] Furthermore, the capacity of the remaining satellite cells to generate muscle cells is diminished owing to epigenetic changes that affect expression of myogenic genes.[11] The ECM sheaths that separate muscle fibers exhibit increased collagen accumulation in contracted muscle, contributing to tissue stiffness.[12]

Presenters also discussed the ability of healthy muscle to adjust the number of sarcomeres per myofibril to optimize filament overlap for force production, achieving a proper sarcomere "setpoint." In individuals with CP, sarcomere setpoint regulation appears disrupted because muscle fascicle lengths can be normal while the number of sarcomeres is significantly reduced. Sarcomeres at longer than optimal lengths may contribute to contracture pathogenesis.[13] This disrupted sarcomere setpoint phenomenon has not been observed in mice or nonhuman primates. Additional research is required to understand mechanisms that regulate sarcomere number and to determine whether disruption of this regulation is common to conditions other than CP.

5 | MEASUREMENT OF CONTRACTURES AND BIOMARKERS

Participants at the meeting presented data on the measurement of musculoskeletal anatomy, joint ROM, musculoskeletal tissue architecture, composition, and biomechanics in relation to contractures. The goniometer is the primary instrument used to measure the joint angles that determine ROM and contracture severity. Video-based motion analysis is also used to measure ROM. Other clinical devices used to measure muscle biomechanical properties were discussed, including the myotonometer to measure muscle tone for individuals with UMN signs.[14] Ultrasound can measure tendon and muscle kinematics, in particular fascicle length and pennation angle in real time during static and dynamic tasks. Ultrasound shear wave elastography provides an indirect estimate of tissue stiffness in localized muscle regions.[15] Electrical impedance myography (EIM), which assesses the muscle-induced alteration in a surface-applied current, is sensitive to myofiber cross-sectional area[16] and thus has the potential to measure myofiber deformability during passive or active stretch, which could be valuable in assessing contracture severity and response to therapy. Magnetic resonance imaging and MR spectroscopy have been used to measure muscle volumes, fascicle length, pennation angle, fat accumulation, edema, fibrosis, and remaining contractile tissue. Other MR techniques such as magnetization transfer, spin–lattice relaxation in the rotating frame, diffusion tensor imaging, and the use of contrast agents may provide more information about contracted muscle.

As previously discussed, defects in the regulation of sarcomere number and length may contribute to contractures. A method for measuring sarcomere length with laser diffraction in patients with CP undergoing surgery has provided valuable information.[17] With this method, the A-bands within muscle fibers act as a diffraction grating to incident laser light, and diffraction spacing represents sarcomere length. The technique currently requires access to muscle by incision, but work is underway to adapt this technique to a needle/small probe.[18] Additional development and research application of contracture-relevant outcome measures and biomarkers are anticipated.

6 | THERAPEUTIC STRATEGIES

Discussions of therapeutic strategies for contractures addressed mechanical treatments (stretching, splinting, and surgical lengthening) as well as pharmacologic approaches. Data were presented from a large natural history study in DMD, revealing that 87% of individuals utilize stretching for contracture prevention or treatment, with or without use of orthoses (R. Willcocks, unpublished data, collected 2010-2018, communicated June, 2019). Even though stretching increases muscle extensibility, stretching regimens performed over periods of months appear not to have clinically important effects on joint ROM.[19,20] Increases in muscle extensibility after stretching programs up to 8 weeks may be due to decreased perception of pain from stretching, resulting in acceptance of greater torque application.[21] Beneficial physiological effects of stretching unrelated to ROM, such as changes in blood flow to the muscle or decreased discomfort, have not been adequately studied. In addition, the effectiveness of stretching regimens carried out over longer periods is unknown.

Nonsurgical treatments that are administered with the goals of improving or preventing further loss of joint ROM also include serial

casting and night splints in children with DMD or spasticity.[22,23] Better understanding of the effects of these treatments on muscle and tendon architecture through studies with ultrasound or MRI may lead to enhancements in their efficacy.

An important perspective was presented at the meeting by the mother of a young man living with DMD. She described her son's struggles when attempting to comply with recommendations for daily stretching and the use of orthotics to prevent contracture development. While parents are willing to do whatever will help their child, she asked that experts prescribe regimes based on their professional judgement and the best available information. Physicians and physical therapists should inform patients of the uncertainty of whether these conservative treatments can prevent or affect contracture progression.[19,20]

Surgical interventions for contractures focus on helping patients maintain function and comfort. Two studies were presented on outcomes after transverse gastrocnemius-soleus recession for equinus gait in children with CP.[24,25] In each study, statistically and clinically significant benefits were found when transverse gastrocnemius-soleus recession was targeted to appropriate patients. In DMD, there is consensus that foot or Achilles tendon surgery may improve gait in boys with significant ankle contracture who are ambulatory and have maintained proximal lower limb strength.[26] Boys with severe ankle contracture tend to have insufficient strength to warrant surgery. Surgery for contractures in nonambulatory patients with DMD is not recommended except to address pain or improve wheelchair positioning.[26]

Several drugs and biologics were discussed that are being explored for their effects in preventing or treating contractures. Studies in animal models of contracture have provided evidence that hyaluronan accumulation in the ECM may alter the viscoelastic properties of muscle, contributing to contracture.[27] Results were presented from a preliminary study[28] of treatment with intramuscular hyaluronidase, an enzyme that degrades ECM hyaluronan in patients with upper limb muscle stiffness and spasticity after cerebral injury who were at risk of developing contractures. In this study, researchers demonstrated reduced muscle stiffness and increased passive and active joint movement, which persisted 3 to 5 months after treatment. Recent work has provided imaging evidence of hyaluronan accumulation in patients with muscle stiffness after cerebral injury, which changes after treatment with hyaluronidase.[29] Also discussed was the follistatin analog FST-288. When it was injected intramuscularly in combination with stretching in a mouse model of immobilization-induced contractures, this compound promoted longitudinal muscle growth.[30]

Research on strategies to address contracture-associated defects in muscle regeneration were also discussed. Satellite cell-derived myoblasts cultured from contracted muscle of patients with CP exhibited reduced fusion and DNA methylation-dependent inhibition of promyogenic signaling pathways. Studies provided evidence that 5-azacytidine, a drug that alters epigenetic programming, largely reversed the fusion deficits of CP myoblasts and restored gene expression patterns consistent with promyogenic states.[11] Further characterization of the defects in muscle and connective tissue cell types in contractures may lead to novel drugs or biologics for contracture prevention or treatment.

7 | FUTURE DIRECTIONS

Discussions at the meeting identified areas of ongoing and future research that may contribute to the level of understanding of contractures required to advance prevention and treatment strategies. To better understand the mechanisms of contracture development, additional studies are required on

- The changes in muscle, tendon, and joint tissues leading up to and associated with contractures by using available technologies including MRI, ultrasound, or EIM to determine fascicle length, pennation angle, and sarcomere number and length, muscle, and tendon biomechanical properties and ECM composition in the conditions for which these parameters have not yet been analyzed
- Proliferative and regenerative capacity or fibrotic potential of progenitor cells in muscle and tendon associated with contractures
- Neurologic activity contributing to spasticity, weakness, altered proprioception, joint pain, and loss of dexterity that are predictors of contractures
- Developing improved animal models of contracture or understanding what makes existing models of disease resistant to contractures.

To better understand why some patients develop contractures early and others do not develop contracture until much later or not at all, additional studies are required of

- The genetic factors associated with contractures within the same musculoskeletal or neurological condition and across different conditions
- Environmental factors such as level of activity/static positioning, pain management, and the effects of long term stretching and other physical therapy regimens
- Prognostic and disease progression biomarkers based on imaging, musculoskeletal tissue composition, electrophysiological measures, biomechanical properties, or body fluid biomolecules.

Knowledge gained through these research avenues can inform the optimization of existing surgical and nonsurgical treatments to lessen the impact of contractures, and these studies may identify targets for the development of novel treatments or preventative measures.

ACKNOWLEDGMENTS

The authors thank Thomas Cheever, PhD (NIAMS/NIH) and Ralph Nitkin, PhD (NICHD/NIH) for their efforts in planning the conference and contributing to this summary and Carsten Bönnemann, MD (NINDS/NIH) for insightful comments on this meeting summary. This workshop was supported by NICHD, NINDS, PPMD and SRAlab. This article summarizes the research findings presented and topics discussed at the meeting.

CONFLICT OF INTEREST

Craig M. McDonald has received support from and/or has served as a paid consultant for Sarepta Therapeutics, PTC Therapeutics, Santhera Pharmaceuticals, Italfarmaco, Pfizer, and Roche. The remaining authors have no conflicts of interest. The views expressed in this article are the opinions of the authors and are not intended to represent of the viewpoint of the National Institutes of Health or its Institutes.

ETHICAL PUBLICATION STATEMENT

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Glen H. Nuckolls https://orcid.org/0000-0002-7466-6433
Seward B. Rutkove https://orcid.org/0000-0002-6375-3312
Leslie F. Vogel https://orcid.org/0000-0002-0414-1228
Richard L. Lieber https://orcid.org/0000-0002-7203-4520

REFERENCES

1. Halar EM, Stolov WC, Venkatesh B, Brozovich FV, Harley JD. Gastrocnemius muscle belly and tendon length in stroke patients and able-bodied persons. *Arch Phys Med Rehabil.* 1978;59:476-484.
2. McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. *Phys Med Rehabil Clin N Am.* 1998;9:187-211.
3. Fry NR, Gough M, Shortland AP. Three-dimensional realisation of muscle morphology and architecture using ultrasound. *Gait Posture.* 2004;20:177-182.
4. Williams EA, Read L, Ellis A, Morris P, Galasko CS. The management of equinus deformity in Duchenne muscular dystrophy. *J Bone Joint Surg Br.* 1984;66:546-550.
5. Matozinho CVO, Teixeira-Salmela LF, Samora GAR, Sant'Anna R, Faria CDCM, Scianni A. Incidence and potential predictors of early onset of upper-limb contractures after stroke. *Disabil Rehabil.* 2019;22:1-7.
6. McDonald CM, Abresch RT, Carter GT, et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. *Am J Phys Med Rehabil.* 1995;74:S70-S92.
7. Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. *Phys Med Rehabil Clin N Am.* 2012;23:675-687.
8. Choi YA, Chun SM, Kim Y, Shin HI. Lower extremity joint contracture according to ambulatory status in children with Duchenne muscular dystrophy. *BMC Musculoskelet Disord.* 2018;19:287.
9. Pingel J, Bartels EM, Nielsen JB. New perspectives on the development of muscle contractures following central motor lesions. *J Physiol.* 2017;595:1027-1038.
10. Dayanidhi S, Dykstra PB, Lyubasyuk V, McKay BR, Chambers HG, Lieber RL. Reduced satellite cell number in situ in muscular contractures from children with cerebral palsy. *J Orthop Res.* 2015;33:1039-1045.
11. Domenighetti AA, Mathewson MA, Pichika R, et al. Loss of myogenic potential and fusion capacity of muscle stem cells isolated from contractured muscle in children with cerebral palsy. *Am J Physiol Cell Physiol.* 2018;315:C247-C257.
12. Smith LR, Lee KS, Ward SR, Chambers HG, Lieber RL. Hamstring contractures in children with spastic cerebral palsy result from a stiffer extracellular matrix and increased in vivo sarcomere length. *J Physiol.* 2011;589:2625-2639.
13. Lieber RL, Fridén J. Spasticity causes a fundamental rearrangement of muscle-joint interaction. *Muscle Nerve.* 2002;25:265-270.
14. Li X, Shin H, Zong Y, Li S, Zhou P. Assessing muscle compliance in stroke with the myotonometer. *Clin Biomech.* 2017;50:110-113.
15. Lee SSM, Gaebler-Spira D, Zhang L-Q, Rymer WZ, Steele KM. Use of shear wave ultrasound elastography to quantify muscle properties in cerebral palsy. *Clin Biomech.* 2016;31:20-28.
16. Kapur K, Nagy JA, Taylor RS, Sanchez B, Rutkove SB. Estimating myofiber size with electrical impedance myography: a study in amyotrophic lateral sclerosis mice. *Muscle Nerve.* 2018;58:713-717.
17. Mathewson MA, Ward SR, Chambers HG, Lieber RL. High resolution muscle measurements provide insights into equinus contractures in patients with cerebral palsy. *J Orthop Res.* 2015;33:33-39.
18. Young KW, Kuo BPP, O'Connor SM, Radic S, Lieber RL. In vivo sarcomere length measurement in whole muscles during passive stretch and twitch contractions. *Biophys J.* 2017;112:805-812.
19. Harvey LA, Katalinic OM, Herbert RD, Moseley AM, Lannin NA, Schurr K. Stretch for the treatment and prevention of contractures. *Cochrane Database Syst Rev.* 2017;9:1-181.
20. Craig J, Hilderman C, Wilson G, Misovic R. Effectiveness of stretch interventions for children with neuromuscular disabilities: evidence-based recommendations. *Pediatr Phys Ther.* 2016;28:262-275.
21. Weppler CH, Magnusson SP. Increasing muscle extensibility: a matter of increasing length or modifying sensation? *Phys Ther.* 2010;90:438-449.
22. Glanzman AM, Flickinger JM, Dholakia KH, Bönnemann CG, Finkel RS. Serial casting for the management of ankle contracture in Duchenne muscular dystrophy. *Pediatr Phys Ther.* 2011;23:275-279.
23. Woo R. Spasticity: orthopedic perspective. *J Child Neurol.* 2001;16:47-53.
24. Dreher T, Buccoliero T, Wolf SI, et al. Long-term results after gastrocnemius-soleus intramuscular aponeurotic recession as a part of multilevel surgery in spastic diplegic cerebral palsy. *J Bone Joint Surg Am.* 2012;94:627-637.
25. Tinney A, Thomason P, Sangeux M, Khot A, Graham HK. The transverse vulpius gastrocsoleus recession for equinus gait in children with cerebral palsy. *Bone Joint J.* 2015;97-B:564-571.
26. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy. Part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol.* 2018;17:347-361.
27. Okita M, Yoshimura T, Nakano J, Motomura M, Eguchi K. Effects of reduced joint mobility on sarcomere length, collagen fibril arrangement in the endomysium, and hyaluronan in rat soleus muscle. *J Muscle Res Cell Motil.* 2004;25:159-166.
28. Raghavan P, Lu Y, Mirchandani M, Stecco A. Human recombinant hyaluronidase injections for upper limb muscle stiffness in individuals with cerebral injury: a case series. *EBioMedicine.* 2016;9:306-313.
29. Menon RG, Raghavan P, Regatte RR. Quantifying muscle glycosaminoglycan levels in patients with post-stroke muscle stiffness using T1ρ MRI. *Sci Rep.* 2019;9:14513.
30. Tinklenberg J, Beatka M, Bain JLW, et al. Use of ankle immobilization in evaluating treatments to promote longitudinal muscle growth in mice. *Muscle Nerve.* 2018;58:718-725.

How to cite this article: Nuckolls GH, Kinnett K, Dayanidhi S, et al. Conference report on contractures in musculoskeletal and neurological conditions. *Muscle Nerve.* 2020;1–5. https://doi.org/10.1002/mus.26845